{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:51:53Z","timestamp":1794696713062,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to describe the experience of a single neuromuscular center in Germany in treating adult spinal muscular atrophy (SMA) patients with risdiplam and to analyze motor function and treatment satisfaction during a follow-up period up to 20\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fourteen patients with type 2 or 3 SMA (seven with SMA type 2, six with SMA type 3; age range: 18\u201351) were included. The Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE) were recorded at baseline and at follow-up (month 4, 8, 12, 16, 20). Treatment adverse events were collected at every follow-up visit. Patients\u2019 treatment satisfaction was assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Half of the patients reached the 20-month follow-up. Based on the HFMSE score, no patients had clinically meaningful improvement. Twelve remained stable (92.3%), two showed transient clinically meaningful deterioration (15.4%) and one experienced lasting clinically meaningful deterioration (7.7%). Based on the RULM scores, seven patients were either stable or demonstrated clinically meaningful improvement (53.8%) and six showed clinically meaningful deterioration (46.2%). There was no treatment withdrawal during the follow-up. The most common adverse events were skin rash\/increased skin sensitivity to sunlight (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), diarrhea (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), aphthous ulcer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) and abdominal pain (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Most patients stated to be at least \u201csatisfied\u201d with the medication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risdiplam was well tolerated. Half of the patients remained stable or improved after risdiplam initiation. Larger and multicentric studies are needed to better understand the long-term effects of risdiplam in adult SMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-024-03562-x","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T02:02:34Z","timestamp":1708135354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction"],"prefix":"10.1186","volume":"24","author":[{"given":"Bogdan","family":"Bjelica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Wohnrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraima","family":"Cespedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Osmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Schreiber-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"issue":"5","key":"3562_CR1","first-page":"1348","volume":"26","author":"JR Nance","year":"2020","unstructured":"Nance JR. Spinal muscular atrophy. Continuum (Minneap Minn). 2020;26(5):1348\u201368.","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"3562_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"1","key":"3562_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Alias","year":"2009","unstructured":"Alias L, Bernal S, Fuentes-Prior P, Barcelo MJ, Also E, Martinez-Hernandez R, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29\u201339.","journal-title":"Hum Genet"},{"issue":"9630","key":"3562_CR4","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333.","journal-title":"Lancet"},{"key":"3562_CR5","unstructured":"Biogen. SPINRAZA (nusinersen) for intrathecal use. December, 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf (Accessed 23 Jan 2023)."},{"key":"3562_CR6","unstructured":"Biogen. Summary of product characteristics. December, 2017. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004312\/WC500229704.pdf (Accessed 11 Nov 2021)"},{"key":"3562_CR7","unstructured":"US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion. May, 2019. https:\/\/www.fda.gov\/media\/126109\/download (Accessed 23 Jan 2023)."},{"key":"3562_CR8","unstructured":"European Medicines Agency. Zolgensma. May, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma (Accessed 23 Jan 2023)."},{"key":"3562_CR9","unstructured":"Genentech Inc. Evrysdi \u00ae (risdiplam) for oral solution: US prescribing information. 2021. https:\/\/www.gene.com\/ (Accessed 23 Jan 2023)."},{"key":"3562_CR10","unstructured":"Roche Registration GmbH. Evrysdi \u00ae (risdiplam) powder for oral solution: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/ (Accessed 23 Jan 2023)."},{"issue":"4","key":"3562_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs. 2022;36(4):401\u201310.","journal-title":"CNS Drugs"},{"issue":"5","key":"3562_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"3562_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"2","key":"3562_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27755","volume":"67","author":"G McCluskey","year":"2023","unstructured":"McCluskey G, Lamb S, Mason S, NicFhirleinn G, Douglas I, Tirupathi S, et al. Risdiplam for the treatment of adults with spinal muscular atrophy: experience of the Northern Ireland neuromuscular service. Muscle Nerve. 2023;67(2):157\u201361.","journal-title":"Muscle Nerve"},{"issue":"5","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NC Nungo Garzon","year":"2023","unstructured":"Nungo Garzon NC, Pitarch Castellano I, Sevilla T, Vazquez-Costa JF. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67(5):407\u201311.","journal-title":"Muscle Nerve"},{"issue":"6","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. Plos One. 2018;13(6):e0199657.","journal-title":"Plos One"},{"issue":"6","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"issue":"12","key":"3562_CR18","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois JM, Bolz S, Kizina K, Totzeck A, Schlag M, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol. 2020;27(12):2586\u201394.","journal-title":"Eur J Neurol"},{"issue":"4","key":"3562_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155\u20139.","journal-title":"Eur J Paediatr Neurol"},{"key":"3562_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outc. 2004;2:12.","journal-title":"Health Qual Life Outc"},{"issue":"2","key":"3562_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, Pereon Y, Cances C, Vuillerot C, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8(2):359\u201373.","journal-title":"Ann Clin Transl Neurol"},{"issue":"18","key":"3562_CR22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79(18):1889\u201397.","journal-title":"Neurology"},{"issue":"4","key":"3562_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, De Sanctis R, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426\u201330.","journal-title":"Muscle Nerve"},{"issue":"5","key":"3562_CR24","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346.","journal-title":"J Neurol"},{"issue":"1","key":"3562_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn A, Gunther R, Ludolph A, Schwartz O, Trollmann R, Weydt P, et al. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2022;17(1):276.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3562_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","volume":"9","author":"JM Kwon","year":"2022","unstructured":"Kwon JM, Arya K, Kuntz N, Phan HC, Sieburg C, Swoboda KJ, et al. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(6):810\u20138.","journal-title":"Ann Clin Transl Neurol"},{"key":"3562_CR27","doi-asserted-by":"publisher","first-page":"175628642199890","DOI":"10.1177\/1756286421998902","volume":"14","author":"A Osmanovic","year":"2021","unstructured":"Osmanovic A, Ranxha G, Kumpe M, Wurster CD, Stolte B, Cordts I, et al. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Ther Adv Neurol Disord. 2021;14:1756286421998902.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03562-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03562-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03562-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T02:03:23Z","timestamp":1708135403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03562-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03562-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3376263\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in strict accordance with the principles outlined in the Declaration of Helsinki and in compliance with all relevant guidelines and regulations governing human research ethics. The study was approved by the Ethical Board of Hannover Medical School (no. 6269) and all patients gave written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BB, CW and IC declare that they have no conflict of interests. AO has received speaker fees from Biogen GmbH outside the submitted work. O.S.-K. received academic research support from the Hannover Medical School (MHH) Young Faculty Program, 2018\u20132020, the \u201cEllen-Schmidt-Program\u201d MHH (2021), and the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Mus-kelkranke\u201d (DGM e.V.), 2019\u20132021 (grant no. Sc 23\/1); and received honoraria as a speaker\/consultant and\/or funding for travel expenses from the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Muskelkranke (DGM e.V.), Biogen GmbH, Biermann Verlag GmbH, and MK\u2009+\u2009S\u2014Medizin, Kommunikation & Service GmbH, outside the submitted work. SP has received speaker fees, non-financial support and research support from Biogen, Roche, AL-S Pharma, Amylyx, Cytokinetics, Ferrer, ITF-Pharma, and Sanofi and served on advisory boards of Amylyx, Biogen, Roche, Zambon and ITF Pharma outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}